Fairvalue-Calculator Fairvalue-Calculator
EN DE

Unicycive Therapeutics, Inc (UNCY) Fair Value & Analysis

Healthcare · US · Market cap $220M

Price$7.89
Fair Value$4.96
Upside-37.1%
Quality95/100
Evidence: Low Range $3.72 – $6.20

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Unicycive Therapeutics, Inc (UNCY) currently trades at $7.89, while our model-based Fair Value estimate is $4.96 — implying the stock looks roughly 37.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Unicycive Therapeutics, Inc (UNCY) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $4.96 versus a price of $7.89 — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of UNCY?
Our 21-model fair value for Unicycive Therapeutics, Inc is $4.96 (as of Jun 25, 2026), built from audited fundamentals. The current price is $7.89.
What is the quality score of UNCY?
Unicycive Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.